Sharon Walsh, PhD

University of Kentucky

Disclosure(s): Astra Zeneca: Advisor/Consultant; Braeburn Pharmaceuticals: Advisor/Consultant; Cerevel Therapeutics: Advisor/Consultant; Indivior: Advisor/Consultant; Reacx: Advisor/Consultant

Poster(s):

• (P-1863) Integrated outpatient treatment of Serious Injection-Related Infections and Opioid Use Disorder: the Buprenorphine plus Outpatient Parenteral Antibiotic Therapy (BOPAT) Clinical Trial
  Wednesday, October 22, 2025

  12:15 PM - 1:30 PM US ET